{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:17:23Z","timestamp":1778771843729,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:00:00Z","timestamp":1497484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:p>The aims of this study were to report treatment outcomes for dogs with histiocytic sarcoma (<jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content>) treated with both lomustine and epirubicin, and to report response rates to epirubicin as a rescue therapy in dogs previously treated with lomustine. Medical records of dogs with a diagnosis of <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> that were treated with both lomustine and epirubicin were retrospectively evaluated. Of 29 dogs receiving epirubicin alternating with, or subsequent to lomustine treatment, including in a rescue setting, response to epirubicin could be assessed in 20 with an overall response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>) of 29% and biological response rate (<jats:styled-content style=\"fixed-case\">BRR<\/jats:styled-content>) of 71%. Median time to progression (<jats:styled-content style=\"fixed-case\">TTP<\/jats:styled-content>) in 12 of these 20 dogs in which it was assessable was 69 days (range: 40\u2010125 days). For dogs treated in the rescue setting epirubicin specific <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> was 19% and <jats:styled-content style=\"fixed-case\">BRR<\/jats:styled-content> 63%. Median <jats:styled-content style=\"fixed-case\">TTP<\/jats:styled-content> in the 9 of these 16 dogs in which it was assessable was 62 days (range: 40\u2010125 days). Median survival time for all dogs treated with both epirubicin and lomustine was 185 days (range: 27\u2010500 days). Some dogs with HS respond to epirubicin and dogs treated with combinations of epirubicin and lomustine have modestly improved survival times compared with single agent studies, and similar to dogs with <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> treated with alternating lomustine and doxorubicin. Single agent epirubicin is also a valid short term rescue therapy for canine HS.<\/jats:p>","DOI":"10.1111\/vco.12329","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T02:12:41Z","timestamp":1497579161000},"source":"Crossref","is-referenced-by-count":15,"title":["Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-1675","authenticated-orcid":false,"given":"S. L.","family":"Mason","sequence":"first","affiliation":[{"name":"Queens Veterinary School Hospital University of Cambridge  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1932-211X","authenticated-orcid":false,"given":"R.","family":"Finotello","sequence":"additional","affiliation":[{"name":"Small Animal Teaching Hospital University of Liverpool  Neston UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Blackwood","sequence":"additional","affiliation":[{"name":"Small Animal Teaching Hospital University of Liverpool  Neston UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,6,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.39-1-74"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300985813510413"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-165X.2012.00449.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.239.1.90"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2009.00186.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2007.tb02937.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2010.0588.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsap.12354"},{"key":"e_1_2_6_10_1","article-title":"Clinical prognostic factors in canine histiocytic sarcoma","author":"Dervisis NG","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2004.tb00138.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.2011.00690.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2011.0743.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050591"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.246.11.1230"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0763-y"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2011.00274.x"},{"key":"e_1_2_6_18_1","first-page":"1789","article-title":"Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T\u2010cell line TALL\u2010104","volume":"10","author":"Visonneau S","year":"1997","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","unstructured":"GanzinaF. \u20184\u2019\u2010epi\u2010doxorubicin. A new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.Cancer Treat. Rev.1983;10(1):1\u201022.","DOI":"10.1016\/S0305-7372(83)80029-2"},{"key":"e_1_2_6_20_1","first-page":"233","article-title":"Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin","volume":"12","author":"Gazina F","year":"1986","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.231.10.1550"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2011.00281.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2011.00311.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032"},{"issue":"4","key":"e_1_2_6_25_1","article-title":"Veterinary cooperative oncology group \u2013 common terminology criteria for adverse events (VCOG\u2010CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","author":"Anonymous","year":"2011","journal-title":"Vet Comp Oncol"},{"issue":"2","key":"e_1_2_6_26_1","doi-asserted-by":"crossref","DOI":"10.1111\/j.1476-5829.2012.00340.x","article-title":"Development of a limited\u2010sampling model for prediction of doxorubicin toxicity in dogs","volume":"12","author":"Wittenburg LA","journal-title":"Vet Comp Oncol"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvco.12329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T19:49:47Z","timestamp":1694980187000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vco.12329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,15]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/vco.12329"],"URL":"https:\/\/doi.org\/10.1111\/vco.12329","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"value":"1476-5810","type":"print"},{"value":"1476-5829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,15]]}}}